|
|
阿帕替尼单药或联合SOX方案及PD-1单抗治疗晚期胃癌的临床进展
|
Abstract:
我国胃癌负担极为沉重，具有分期晚、肿瘤负荷大、异质性强及预后差等特点，大多数患者确诊时已经处于晚期。晚期胃癌患者既往一线标准化疗带来的生存获益非常有限，随着抗肿瘤靶向药物的发展，抗血管靶向药物倍受关注。血管内皮生长因子受体抑制剂阿帕替尼，可靶向胃癌组织的新生血管，延缓其生长速度，从而抑制晚期胃癌的进一步恶化。本文将对阿帕替尼单药或联合SOX方案及PD-1单抗治疗晚期胃癌的临床进展作一综述。
The burden of gastric cancer in China is extremely heavy, with the characteristics of late staging, large tumor burden, strong heterogeneity and poor prognosis, and most patients are already at an advanced stage when they are diagnosed. The survival benefit of the previous first-line standard chemotherapy in patients with advanced gastric cancer is very limited, and with the development of anti-tumor targeted drugs, anti-vascular targeted drugs have attracted much attention. Apatinib, a vascular endothelial growth factor receptor inhibitor, can target the new blood vessels of gastric cancer tissues, delay their growth rate, and thus inhibit the further progression of advanced gastric cancer. This article reviews the clinical progress of apatinib monotherapy or combination with SOX regimen and PD-1 monoclonal antibody in the treatment of advanced gastric cancer.
| [1] | 中国抗癌协会胃癌专业委员会, 中国医师协会外科医师分会上消化道外科医师委员会, 中国人群健康风险管理协作组-胃癌专业组. 中国人群胃癌风险管理公众指南(2023版) [J]. 中华医学杂志, 2023, 103(36): 2837-2849. |
| [2] | Macedo, F., Kátia, L., Longatto-Filho, A., et al. (2017) Gastric Cancer and Angiogenesis: Is VEGF a Useful Biomarker to Assess Progression and Remission? Journal of Gastric Cancer, 17, 1-10. https://doi.org/10.5230/jgc.2017.17.e1 |
| [3] | 杜京涛, 许新华. 血管内皮生长因子在肿瘤中的研究进展[J]. 肿瘤防治研究, 2009, 36(2): 162-165. https://doi.org/10.3971/J.issn.1000-8578.2009.02.023 |
| [4] | 陈淑慧, 阳帆帆, 何君, 等. 胃癌靶向治疗研究最新进展[J]. 中国临床药理学与治疗学, 2015, 20(8): 950-955. |
| [5] | Liu, X., Zheng, Q., Yu, Q., et al. (2020) Apatinib Regulates the Growth of Gastric Cancer Cells by Modulating Apoptosis and Autophagy. Naunyn-Schmiedeberg’s Archives of Pharmacology, 394, 1009-1018. |
| [6] | Chen, R., Chen, Q.T. and Dong, Y.H. (2019) Clinical Efficacy of Apatinib in Treating Metastatic Gastric Cancer and Its Effect on IL17. Oncology Letters, 17, 5447-5452. https://doi.org/10.3892/ol.2019.10270 |
| [7] | Li, J., Qin, S., Xu, J., et al. (2016) Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients with Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction. Journal of Clinical Oncology, 34, 1448-1454. https://doi.org/10.1200/JCO.2015.63.5995 |
| [8] | 张鹏. 阿帕替尼联合SOX方案对晚期胃癌患者血清 HIF-1α？VEGF及血常规指标的影响[J]. 内蒙古医学杂志, 2023, 55(1): 31-33 37. https://doi.org/10.16096/J.cnki.nmgyxzz.2023.55.01.009 |
| [9] | Zheng, Y., Yang, X., Shi, H., et al. (2018) A Phase II Trial of Neoadjuvant Therapy Using Apatinib plus SOX Regimen in Locally Advanced Gastric Cancer: Updated Results. Annals of Oncology, 29, 226-227. https://doi.org/10.1093/annonc/mdy282.057 |
| [10] | 王璐, 鲁培, 王朝杰, 等. 阿帕替尼联合SOX方案治疗老年晚期胃癌的临床观察[J]. 河南医学研究, 2018, 27(23): 4245-4247. |
| [11] | Xu, J.M., Zhang, Y., Jia, R., et al. (2019) Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-Label, Dose Escalation and Expansion Study. Clinical Cancer Research, 25, 515-523. https://doi.org/10.1158/1078-0432.CCR-18-2484 |
| [12] | 李元元, 刘海鹏, 沈亦敏, 等. 程序性死亡受体1抑制剂联合化疗在晚期胃癌中的研究进展[J]. 中国临床研究, 2023, 36(9): 1342-1347. https://doi.org/10.13429/j.cnki.cjcr.2023.09.013 |
| [13] | Kawazoe, A., et al. (2020) Lenvatinib plus Pembrolizumab in Patients with Advanced Gastric Cancer in the First-Line or Second-Line Setting (EPOC1706): An Open-Label, Single-Arm, Phase 2 Trial. The Lancet Oncology, 21, 1057-1065. https://doi.org/10.1016/S1470-2045(20)30271-0 |
| [14] | Wang, K.X., Cui, T.Y., Yang, X.D., Wang, G.Q., Jiang, Q.S., Sun, H., et al. (2021) Study on Efficacy and Safety of Low-Dose Apatinib Combined with Camrelizumab and SOX Regimen as First-Line Treatment of Locally Advanced and Unresectable Gastric/Gastroesophageal Junction Cancer: A Protocol for an Open-Label, Dose Escalation and Extension Phase Ib Clinical Trial. OncoTargets and Therapy, 14, 4859-4865. https://doi.org/10.2147/OTT.S316288 |
| [15] | Lee, H.J., Moon, J.Y. and Baek, S.W. (2016) Is Treatment-Emergent Toxicity a Biomarker of Efficacy of Apatinib in Gastric Cancer? Journal of Clinical Oncology, 34, 3823-3823. https://doi.org/10.1200/JCO.2016.68.8663 |
| [16] | 秦叔逵, 李进. 阿帕替尼治疗胃癌的临床应用专家共识[J]. 临床肿瘤学杂志, 2015, 20(9): 841-847. |
| [17] | 唐琳, 刘波. 阿帕替尼单药或联合其他方式治疗晚期胃癌的临床研究进展[J]. 社区医学杂志, 2022, 20(10): 586-590. https://doi.org/10.19790/j.cnki.JCM.2022.10.13 |
| [18] | 李丽丽, 孟宪萍, 王贵娣, 等. 应用甲磺酸阿帕替尼治疗转移性胃癌患者不良反应的护理[J]. 解放军护理杂志, 2016, 33(23): 64-66. |
| [19] | Ren, Z., Zhu, K., Kang, H., et al. (2015) Randomized Controlled Trial of the Prophylactic Effect of Urea-Based Cream on Sorafenib-Associated Hand-Foot Skin Reactions in Patients with Advanced Hepatocellular Carcinoma. Journal of Clinical Oncology, 33, 894-900. https://doi.org/10.1200/JCO.2013.52.9651 |
| [20] | Zhang, M., Deng, W., Cao, X., et al. (2017) Concurrent Apatinib and Local Radiation Therapy for Advanced Gastric Cancer: A Case Report and Review of the Literature. Medicine, 96, e6241. https://doi.org/10.1097/MD.0000000000006241 |
